pegaspargase + cyclophosphamide + vincristine + etoposide + prednisone

This drug is a **combination chemotherapy regimen** composed of pegaspargase, cyclophosphamide, vincristine, etoposide, and prednisone, commonly referred to in literature as "pegaspargase-COEP". Each component acts via distinct mechanisms to maximize cancer cell kill: - Pegaspargase is an enzyme that depletes asparagine, an amino acid essential for lymphoid malignancies. - Cyclophosphamide is an alkylating agent that cross-links DNA, interrupting cell division. - Vincristine is a vinca alkaloid that inhibits microtubule assembly, arresting mitosis. - Etoposide inhibits topoisomerase II, leading to DNA strand breaks. - Prednisone is a synthetic glucocorticoid that induces apoptosis and exerts anti-inflammatory and immunosuppressive effects. This regimen has been studied in **newly diagnosed extranodal NK/T-cell lymphoma, nasal type (ENKTL)** where it is often combined with radiotherapy. Phase II clinical data report high efficacy and an acceptable safety profile for this combination[8][2]. The combined mechanisms produce additive or synergistic cytotoxic effects, targeting lymphoma cells through distinct biochemical pathways. Pegaspargase-based regimens have been favored in certain lymphoma types for improved tolerability over non-pegylated asparaginase.

Other names

pegaspargase-COEP